Treatment Clinical Trials for Cervical Cancer

Clinical trials are research studies that involve people. The clinical trials on this list are for cervical cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-70 of 70

  • Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants with Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

    This phase I trial studies how well stereotactic body radiation therapy works in combination with tremelimumab and durvalumab in treating participants with cervical, vaginal, or vulvar cancers that have come back or spread to other areas of the body. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as tremelimumab and durvalumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving stereotactic body radiation therapy, tremelimumab, and durvalumab may work better in treating participants with cervical, vaginal, or vulvar cancers.
    Location: 2 locations

  • DNA Plasmid-encoding Interleukin-12 / HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients with Recurrent or Metastatic Human Papillomavirus Associated Cancers

    This phase II trial studies how well deoxyribonucleic acid (DNA) plasmid-encoding interleukin-12 / human papillomavirus (HPV) DNA plasmids therapeutic vaccine INO-3112 and durvalumab work in treating patients with human papillomavirus associated cancers that have come back or spread to other places in the body. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving DNA plasmid-encoding interleukin-12 / HPV DNA plasmids therapeutic vaccine INO-3112 and durvalumab may work better in treating patients with human papillomavirus associated cancers.
    Location: M D Anderson Cancer Center, Houston, Texas

  • M7824 in Subjects With HPV Associated Malignancies

    Background: In the United States, each year there are more than 30,000 cases of human papillomavirus (HPV) associated cancers. Some of these cancers are often incurable and are not improved by standard therapies. Researchers want to see if a new drug M7824, which targets and blocks a pathway that prevents the immune system from effectively fighting the cancer can shrink tumors in people with some HPV cancers. Objectives: To see if the drug M7824 causes tumors to shrink. Eligibility: Adults age 18 and older who have a cancer associated with HPV infection. Design: Participants will be screened with medical history and physical exam. They will review their symptoms and how they perform normal activities. They will have body scans. They will give blood and urine samples. They will have a sample of their tumor tissue taken if one is not available. Participants will have an electrocardiogram to evaluate their heart. Then they will get the study drug through a thin tube in an arm vein. Participants will get the drug every 2 weeks for 26 times (1 year). This is 1 course. After the course, participants will be monitored but will not take the study drug. If their condition gets worse, they will start another course with the drug. This process can be repeated as many times as needed. Treatment will stop if the participant has bad side effects or the drug stops working. Throughout the study, participants will repeat some or all the screening tests. After participants stop taking the drug, they will have a follow-up visit and repeat some screening tests. They will get periodic follow-up phone calls. ...
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

    This is an open-label, Phase 1, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of ABBV-321 for participants with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR). The study will consist of 2 phases: Dose Escalation Phase and Expansion Phase.
    Location: Duke University Medical Center, Durham, North Carolina

  • Text or Voice Messages in Improving Physical Activity in Cancer Survivors

    This pilot clinical trial studies how well text or voice messages work in improving physical activity in cancer survivors. Physical activity may protect from cancer and may even reduce the risk of cancer recurrence. New technology, such as text and voice messages, may help cancer survivors to become more active.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Atezolizumab and Bevacizumab in Treating Patients with Rare Solid Tumors

    This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Magnetic Resonance Imaging-Guided Brachytherapy in Treating Patients with Gynecologic Cancers

    This pilot clinical trial studies how well magnetic resonance imaging-guided brachytherapy works in treating patients with gynecologic cancer. Magnetic resonance imaging may be able to successfully guide the placement of the brachytherapy applicator and may help in assessing the tumor better at the time of brachytherapy as compared to routinely used computed tomography scan in treating gynecologic cancers.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Metformin Hydrochloride and Doxycycline in Treating Patients with Localized Breast, Uterine, or Cervical Cancer

    This phase II trial studies how well metformin hydrochloride works together with doxycycline in treating patients with localized breast, uterine, or cervical cancer. Metformin hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Doxycycline may stop the growth of bacteria by keeping them from making proteins and minimized the toxic side effects of anti-cancer therapy. It is not yet known whether giving metformin hydrochloride together with doxycycline may be a better way in treating patients with localized breast, uterine, or cervical cancer.
    Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

  • Vaccine Therapy and Cyclophosphamide in Treating Patients with HLA-A*02 Positive Relapsed, Refractory, or Metastatic HPV16-Related Oropharyngeal, Cervical, or Anal Cancer

    This phase Ib / II trial studies side effects and best dose of HPV16-E711-19 nanomer vaccine DPX-E7 and to see how well it works when given together with cyclophosphamide in treating patients with HLA-A*02 positive, human papillomavirus 16 (HPV16)-related oropharyngeal, cervical, or anal cancer that has come back, does not respond to treatment, or has spread to other parts of the body. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving HPV16-E711-19 nanomer vaccine DPX-E7 together with cyclophosphamide may work better in treating patients with HPV16-related oropharyngeal, cervical, or anal cancer.
    Location: Dana-Farber Cancer Institute, Boston, Massachusetts

  • Dose Escalation Study of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma

    The study drug, GSK3326595, is an inhibitor of protein arginine methyltransferase 5 (PRMT5) that potently inhibits tumor growth in vitro and in vivo in animal models. This first time in human (FTIH), open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in subjects with advanced or recurrent solid tumors, as well as clinical activity in subjects with a subset of solid tumors and non-Hodgkin's lymphoma. This is an open-label, repeat-dose, multicenter, 2-part study to establish the maximally tolerated dose (MTD) / recommended phase 2 dose (RP2D) based on safety and tolerability and preliminary clinical efficacy of orally-administered GSK3326595. Part 1 is a dose-escalation phase to identify the MTD / RP2D based on the safety, PK, and PD profiles observed after oral administration of GSK3326595 and to preliminarily identify whether or not there is an effect of fed versus fasted state on the PK of GSK3326595. This Part will be conducted in adult subjects with relapsed and / or refractory solid tumors. It is estimated that up to 66 subjects will be enrolled into the dose escalation cohort of the study, including up to 42 subjects to identify the MTD and approximately 12 subjects in the PK / PD / metabolite / biomarker expansion cohort(s) and approximately 12 subjects in the food effect sub-study. Disease-specific expansion cohorts (Part 2) are planned to further explore clinical activity of GSK3326595 in subjects with selected solid tumors and non-Hodgkin's lymphomas. It is estimated that up to 251 subjects will be enrolled in the disease-specific expansion cohorts of the study. The duration of study will depend on recruitment rates and the timing of subjects' duration on study (withdrawal rates due to toxicity or progression), with an approximate duration of 2 years.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Eribulin Mesylate in Treating Patients with Advanced or Recurrent Cervical Cancer

    This phase II trial studies how well eribulin mesylate works in treating patients with cervical cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has come back (recurrent). Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California

  • Intensity-Modulated Radiation Therapy, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients with Stage IB-IVA Cervical Cancer

    This phase I trial studies the side effects and best dose of gemcitabine hydrochloride when given together with intensity-modulated radiation therapy and cisplatin in treating patients with stage IB-IVA cervical cancer. Drugs used chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Specialized radiation therapy, such as intensity-modulated radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving chemotherapy together with intensity-modulated radiation therapy may kill more tumor cells.
    Location: University of California San Diego, San Diego, California

  • Basket Study to Evaluate the Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Advanced and / or Metastatic Solid Tumors

    This is an open-label, multicenter, basket trial Phase II study to evaluate the antitumor activity of RO6874281 in combination with atezolizumab in participants with advanced and / or metastatic solid tumors. Currently the focus is on patients with Head and Neck, oesophageal and cervical cancers with confirmed squamous cell carcinoma histology type.
    Location: 2 locations

  • Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

    The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Phase 1 / 2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)

    The purpose of Part 1 (Phase 1b) is to evaluate the general safety and tolerability of repeated 21-day cycles of AL3818 therapy, and to reevaluate the maximum tolerated dose (MTD). The purpose of Part 2 (Phase 2a) is to evaluate the efficacy of repeated 21-day cycles of AL3818 therapy preliminary efficacy of AL3818 in subjects with recurrent or metastatic endometrial, ovarian or cervical cancer.
    Location: See Clinical Trials.gov

  • Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer

    Current standard treatment for locally advanced cervical cancer is cisplatin-based concurrent chemoradiation (CRT). Although recently reported meta-analysis studies also demonstrated improved local control rates and survival with cisplatin-based chemotherapy concurrent to radiation therapy (RT), the optimal cisplatin dose and dosing schedule are still undetermined. In light of the results of the previous clinical trial, weekly cisplatin 40 mg / m2 considered to be a standard regiment in cisplatin doses and dosing schedules. However, our randomized phase II trial showed that tri-weekly cisplatin 75mg / m2 has lower toxicities and a better outcome in locally advanced cervical cancer. In this randomized phase III trial, the investigators investigate that there may be a survival difference between weekly cisplatin 40 mg / m2 and tri-weekly cisplatin 75 mg / m2 administration concurrent to RT in cervical cancer.
    Location: See Clinical Trials.gov

  • A Study of XmAb®22841 Monotherapy & in Combination w / Pembrolizumab in Subjects w / Selected Advanced Solid Tumors

    This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and / or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.
    Location: 3 locations

  • Artesunate in Treating Patients With Solid Tumors

    This phase I trial studies the side effects and best dose of artesunate in treating patients with solid tumors. Artesunate may help treat cancer caused by the human papillomavirus.
    Location: MedStar Georgetown University Hospital, Washington, District of Columbia

  • Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer

    Part A: (ADXS11-001 + MEDI4736 Combination Therapy) will determine the safety and tolerability of the combination and to identify a RP2D. Part B: Phase 2 design which will randomize subjects 1:1 to either MEDI4736 alone or MEDI4736+ADXS11-001 in subjects who have failed at least 1 prior systemic treatment for their recurrent / persistent or metastatic cervical cancer.
    Location: 5 locations

  • Nab-Paclitaxel and Bevacizumab in Treating Patients with Unresectable Stage IV Melanoma or Gynecological Cancers

    This phase I trial studies the side effects and best dose of nab-paclitaxel and bevacizumab in treating patients with stage IV melanoma that cannot be removed by surgery or with cancer of the cervix, endometrium, ovary, fallopian tube or peritoneal cavity. Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as bevacizumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving nab-paclitaxel and bevacizumab may kill more tumor cells than nab-paclitaxel alone.
    Location: Mayo Clinic, Rochester, Minnesota